Trials / Unknown
UnknownNCT04322513
Biomarkers for Identification of COVID-19 Infection
Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 110 (estimated)
- Sponsor
- University of Catanzaro · Academic / Other
- Sex
- All
- Age
- 14 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Acute lung injury represents the most severe form of the viral infection sustained by coronavirus disease 2019 (Covid-19) also named as SARS-CoV-2, a new virus emerged in December 2019 in Wuhan (China). The diagnosis is clinical and patients develop flu-like syndrome with fever and cough; patients with clinical symptoms can perform a swab test, including molecular and/or antigen swab, for diagnosis of positivity to Covid-19. Even if diagnosis and treatment are well described, to date, this viral pandemic infection induces an increased mortality in the world. The aim of the present project is to evaluate specific biomarkers that could be used for patient stratification and for tailor therapy in COVID-19 infected patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Biomarkers expression | Evaluation in biomarkers expression between 2 groups |
Timeline
- Start date
- 2020-03-24
- Primary completion
- 2021-06-30
- Completion
- 2022-12-30
- First posted
- 2020-03-26
- Last updated
- 2021-10-25
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04322513. Inclusion in this directory is not an endorsement.